ASC30

Phase 2Small molecule

AAscletis Pharma (China) Co., Limited

ASC30 is one of 68 small molecule programs targeting Type 2 Diabetes Mellitus. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Type 2 Diabetes MellitusActive, not recruiting

ObesityActive, not recruiting

Type 2 Diabetes MellitusPhase 2

Active, not recruiting

ObesityPhase 1

Active, not recruiting

Competition

Competitive Landscape

676 competitors in Type 2 Diabetes Mellitus

#DrugCompanyPhaseTrials

Insulin 320

Novo Nordisk

Preclinical

43 2

NOVOLIN R

Novo Nordisk

Preclinical

1 3

Adenocard

Astellas

Preclinical

1 4

Dostinex

Golytely

Myrbetriq

Lantus

6 8

ASC30

AAscletis Pharma (China) Co., Limited

Phase 2

1 9

Lixisenatide

Sanofi

Preclinical

4 10

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Recruiting

Type 2 Diabetes Mellitus

NCT07321678

Clinical

Trials by Indication[1]

Obesity1 trial

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of ASC30 Tablets and ASC30 Tablets A1 in Participants With Obesity

Completed·AAscletis Pharma (China) Co., Limited·Phase 1·NCT06680440·72 enrolled

Type 2 Diabetes Mellitus1 trial

A Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes Mellitus

Recruiting·AAscletis Pharma (China) Co., Limited·Phase 2·NCT07321678·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for ASC30. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ASC30 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ASC30. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ascletis Pharma (China) Co., Limited company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAscletis Pharma (China) Co., Limited

ASC30

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Obesity1 trial

Type 2 Diabetes Mellitus1 trial

References

Drug Info

Quick Facts

Related News